NCT05173298View on ClinicalTrials.gov

Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

atezolizumab plus bevacizumab

1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks

Trial Locations (1)

13496

RECRUITING

CHA Bundang Medical Center, Seongnam-si

Sponsors
All Listed Sponsors
collaborator

Boryung Pharmaceutical Co., Ltd

INDUSTRY

lead

CHA University

OTHER

NCT05173298 - Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab | Biotech Hunter | Biotech Hunter